MediWound Reports Q3 2026 Financial Results Amid Clinical Trial Expansion
MediWound (MDWD) reported third-quarter revenue of $3.6 million, a decrease driven primarily by lower development services revenue from the U.S. government. The company recorded a net loss of $6 million ($0.47 per share), impacted by increased research and development spending totaling $6.2 million for its EscharEx Phase III VALUE trial. Despite the losses, the company is strengthening its balance sheet through a recent $17.25 million public offering and has secured an additional $3.3 million in nondilutive funding from the U.S. Department of War for its NexoBrid program. Management noted that while global demand currently exceeds manufacturing capacity, they expect expanded production capabilities to be operational by late 2026.
Topics: cash burn clinical trials net loss public offering revenue